<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10363104</article-id><article-id pub-id-type="pmcid-ver">PMC10363104.1</article-id><article-id pub-id-type="pmcaid">10363104</article-id><article-id pub-id-type="pmcaiid">10363104</article-id><article-id pub-id-type="pmid">37481659</article-id><article-id pub-id-type="doi">10.1038/s41598-023-39126-1</article-id><article-id pub-id-type="publisher-id">39126</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Association between urinary caffeine and caffeine metabolites and stroke in American adults: a cross-sectional study from the NHANES, 2009&#8211;2014</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Fan</surname><given-names initials="J">Jinming</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Yuan</surname><given-names initials="Y">Yajun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="X">Xiaoting</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="W">Wenhan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ma</surname><given-names initials="W">Wuqin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="W">Wenhao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Gu</surname><given-names initials="J">Jinyan</given-names></name><address><email>gujy9@mail.sysu.edu.cn</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhou</surname><given-names initials="B">Bin</given-names></name><address><email>zhoub2@mail.sysu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.452859.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 6006 3273</institution-id><institution>Center of Cerebrovascular Disease, </institution><institution>The Fifth Affiliated Hospital of Sun Yat-Sen University, </institution></institution-wrap>Zhuhai, 519000 Guangdong Province China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.452859.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 6006 3273</institution-id><institution>Center of Interventional Medicine, </institution><institution>The Fifth Affiliated Hospital of Sun Yat-Sen University, </institution></institution-wrap>Zhuhai, 519000 Guangdong Province China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.452859.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 6006 3273</institution-id><institution>Department of Scientific Research, </institution><institution>The Fifth Affiliated Hospital of Sun Yat-Sen University, </institution></institution-wrap>Zhuhai, 519000 Guangdong Province China </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>7</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>13</volume><issue-id pub-id-type="pmc-issue-id">425018</issue-id><elocation-id>11855</elocation-id><history><date date-type="received"><day>9</day><month>5</month><year>2023</year></date><date date-type="accepted"><day>20</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>07</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>24</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-17 14:25:39.347"><day>17</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2023_Article_39126.pdf"/><abstract id="Abs1"><p id="Par1">This study investigates the potential correlation between urinary caffeine levels and the occurrence of stroke, a serious cerebrovascular disease that can lead to disability or death. The data used in this study was obtained from the National Health and Nutrition Examination Survey conducted between 2009 and 2014. The study analyzed a total of 5,339 individuals, divided into a control group (n&#8201;=&#8201;5,135) and a stroke group (n&#8201;=&#8201;162). The researchers utilized multiple logistic regression and smoothed curve fitting to examine the relationship between urinary caffeine and caffeine metabolites and the incidence of stroke. The study found that higher urinary caffeine levels were associated with a lower risk of stroke in Mexican American participants (odds ratio [OR]&#8201;=&#8201;0.886, 95% confidence interval [CI]: (0.791, 0.993), <italic toggle="yes">P</italic>&#8201;=&#8201;0.037). After adjusting for certain participant characteristics, it was also found that higher urinary paraxanthine levels were associated with a lower risk of stroke incidence (OR&#8201;=&#8201;0.991, 95% CI (0.984, 0.999), <italic toggle="yes">P</italic>&#8201;=&#8201;0.027). Meanwhile, the highest urinary paraxanthine levels group had 43.7% fewer strokes than the lowest level group (OR&#8201;=&#8201;0.563, 95% CI (0.341, 0.929), <italic toggle="yes">P</italic>&#8201;=&#8201;0.025). In this study, we showed a negative link between urine paraxanthine levels and the risk of stroke. Meanwhile, urinary caffeine levels were negatively associated with the incidence of stroke in Mexican Americans, but no correlation in other populations. Our findings may have predictive and diagnostic implications in clinical practice. Further extensive prospective investigations are still needed to validate our conclusions.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Biomarkers</kwd><kwd>Diseases</kwd><kwd>Neurology</kwd><kwd>Risk factors</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82102164</award-id><principal-award-recipient><name name-style="western"><surname>Zhou</surname><given-names>Bin</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Stroke is an acute cerebrovascular disease that can cause limb paralysis, speech impairment, impaired consciousness, and death. The burden of stroke is increasing<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>, and in 2019 it will continue to be the third greatest cause of death and disability combined (5.7% [5.1&#8211;6.2] of total disability-adjusted life years) and the second major cause of death (11.6% [10.8&#8211;12.2] of total deaths)<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Therefore, it is crucial from a therapeutic perspective to recognize and treat stroke patients' risk factors. Old age, diabetes, high cholesterol, smoking, a high body mass index (BMI), coronary heart disease, high blood pressure, etc.<sup><xref ref-type="bibr" rid="CR3">3</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref></sup>.</p><p id="Par3">Coffee beans, tea leaves, cocoa beans, and cola nuts are among the plants that contain caffeine (chemical name: 1,3,7-trimethylxanthine), an alkaloid. We consume caffeine daily, mainly through food and drinks (e.g., chocolate, coffee, tea, and cola drinks)<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>. Studies have shown that coffee is currently consumed by many age groups in the U.S. population and that daily caffeine intake is relatively stable over the week, with no significant differences between weekdays and weekend days<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Several diseases&#160;have&#160;been&#160;reported to be associated with&#160;caffeine&#160;consumption,&#160;including bone density issues, high blood pressure, cardiovascular disease, reproductive and developmental abnormalities, mental and behavioral disorders, and various cancers<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. Caffeine is a central nervous system stimulant and is believed to provide health benefits in cardiovascular, cerebrovascular, and neurological diseases<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>. Some studies have reported that caffeine may be associated with antioxidant activity, regulation of metabolism, and improvement of endothelial function. More than three cups of coffee a day, according to a study, may lower your risk of developing Alzheimer's and Parkinson's disease<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Several studies have shown that caffeine consumption is associated with a reduced incidence of stroke<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Caffeine's antioxidant properties, which control cell proliferation and death, may be to blame for this. However, it is thought that caffeine consumption decreases cerebral blood flow in people who have had ischemic strokes, which has a negative therapeutic impact<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>.</p><p id="Par4">Most studies have only focused on the effect of coffee consumption on stroke, and a few have evaluated the relationship between caffeine metabolites and stroke<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Studies on coffee consumption usually estimate caffeine content based on the diet type and volume/weight, while ignoring differences owing to raw material variety, origin, and production process; thus, caffeine consumption is less accurately recorded. Additionally, self-reported caffeine intake, which is prone to significant error, has hampered earlier research on the long-term effects of caffeine<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. A trustworthy indicator of caffeine use is the amount of excreted caffeine and caffeine metabolites in urine, and information about the physiological endpoints of the metabolites clarifies the evidence linking the original chemical and the underlying condition<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. This may lead to some bias in determining the relationship between caffeine and stroke. Additionally, individual variations in caffeine metabolism were overlooked, which may have led to varying concentrations of circulating caffeine and caffeine metabolites<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. To further understand the connection between urine caffeine and caffeine metabolites and the likelihood of stroke, we conducted a cross-sectional study utilizing information from the National Health and Nutrition Examination Survey (NHANES) (2009&#8211;2014).</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study population</title><p id="Par5">NHANES is a cross-sectional nutrition survey in the USA that uses a multistage stratified probability sampling method<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. The NHANES has received approval from the National Center for Health Statistics to collect and disseminate data. Adults (aged&#8201;&#8805;&#8201;20&#160;years) who participated in NHANES from 2009 to 2014 were selected for this study. Individuals without prior information on urinary caffeine and caffeine metabolites and stroke. Authors cannot access information that could identify individual participants during or after data collection. The detailed NHANES study design and data are publicly available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/nhanes/">https://www.cdc.gov/nchs/nhanes/</ext-link>.</p><p id="Par6">Data from a total of 30,465 participants between 2009 and 2014 were initially included in this study. Participants younger than 20&#160;years old were excluded (n&#8201;=&#8201;12,918). Participants with incomplete data of stroke (n&#8201;=&#8201;18), and caffeine and caffeine metabolites (n&#8201;=&#8201;12,190) were excluded. Finally, 5339 participants were included (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Flowchart of participants selection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="41598_2023_39126_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec4"><title>Exposure variable</title><p id="Par7">In this study, urinary levels of caffeine and caffeine metabolites were used as the exposure variable. Theobromine (3,7-dimethylxanthine), theophylline (1,3-dimethylxanthine), and paraxanthine (1,7-dimethylxanthine) are the primary caffeine metabolites in humans<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. After a 9-h overnight fast, urine samples for the study participants were taken during the morning session<sup><xref ref-type="bibr" rid="CR22">22</xref>&#8211;<xref ref-type="bibr" rid="CR24">24</xref></sup>. The National Center for Environmental Health, Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, GA received the processed, stored, and sent urine samples for examination<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Using high-performance liquid chromatography-electrospray ionization-tandem quadrupole mass spectrometry (HPLC&#8211;ESI&#8211;MS/MS) and internal standards labeled with stable isotopes, caffeine and its metabolites are measured in urine<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. The data were reviewed. The performing laboratory received uncertain values or incomplete data for verification<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>.</p></sec><sec id="Sec5"><title>Outcome variable</title><p id="Par8">Using the Computer-Assisted Personal Interviewing (CAPI) technology, stroke history was gathered from patients by trained interviewers. The survey questionnaire is available on the NHANES website. Consistency checks are included into the CAPI system to minimize data entry errors. The information was checked and updated for consistency, completeness, and unreasonable values.</p></sec><sec id="Sec6"><title>Covariates</title><p id="Par9">This study included covariates that may influence the relationship between caffeine and caffeine metabolites and stroke, including data on sex, age, race, history of high blood pressure, history of high cholesterol levels, history of diabetes, history of coronary heart disease, smoking at least 100 cigarettes in life (%), having 4/5 or more drinks every day, and BMI (kg/m<sup>2</sup>). BMI is calculated by weight/height squared. The Mobile Examination Center's qualified health technicians collected the body measurements data. Other covariates were collected through the CAPI system as the outcome variables. Details about covariates are available on the NHANES website (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cdc.gov/nchs/nhanes/">http://www.cdc.gov/nchs/nhanes/</ext-link>).</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par10">With a <italic toggle="yes">P</italic>-value&#8201;&lt;&#8201;0.05 being considered significant, we ran the analyses using the software R (http:// <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.Rproject.org">www.Rproject.org</ext-link>) and EmpowerStats (http:// www. empowerstats.com). Missing continuous variables are excluded, while missing categorical variables form a separate classification. Measurement data were described as mean&#8201;&#177;&#8201;standard deviation (mean&#8201;&#177;&#8201;SD), and comparisons between groups were made using independent sample t-tests. Data that did not conform to a normal distribution differences between groups were compared using the Kruskal&#8211;Wallis rank sum test. An enumeration dataset was described as n (%), and chi-square tests were conducted to compare differences between groups. Multivariate logistic regression analysis was performed to evaluate the association between urinary levels of caffeine and caffeine metabolites and stroke. An unadjusted model (Model 1) was then created, followed by an adjusted model (Model 2) using variables including sex, age, and race or ethnicity. We obtained Model 3 by adjusting for sex, age, race, history of high blood pressure, history of high cholesterol levels, history of diabetes, history of coronary heart disease, smoking at least 100 cigarettes in life (%), having 4/5 or more drinks every day, and BMI (kg/m<sup>2</sup>). The relationship between caffeine and its metabolites in urine and stroke was further clarified by analysing various covariates. A simultaneous smoothed curve fitting was done to further investigate the association between caffeine and caffeine metabolite levels and stroke after controlling for a number of variables.</p></sec><sec id="Sec8"><title>Ethical approval</title><p id="Par11">The data for this study were obtained from NHANES website. Therefore, it does not need to be approved by the Institutional Review Board (or Ethics Committee).</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>The characteristics of participants</title><p id="Par12">The final participants included were divided into a control group (n&#8201;=&#8201;5135) and a stroke group (n&#8201;=&#8201;162). Significant differences in baseline characteristics were observed between the two groups, except for sex, BMI, and urinary caffeine. The participants in the stroke group were older (64.080&#8201;&#177;&#8201;14.251 vs. 48.461&#8201;&#177;&#8201;17.286&#160;years, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) and had lower caffeine metabolites levels in urine (all <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) than those in the control group. Participants in the stroke group were more likely to have high blood pressure, high cholesterol levels, diabetes, coronary heart disease, and a history of smoking and drinking (all <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). In addition, there are some differences in the ethnic distribution of the two groups (<italic toggle="yes">P</italic>&#8201;=&#8201;0.002) (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Basic characteristics and urinary levels of caffeine and caffeine metabolites in study participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="left" colspan="1" rowspan="1">Control group (n&#8201;=&#8201;5135)</th><th align="left" colspan="1" rowspan="1">Stroke group (n&#8201;=&#8201;162)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1">48.461&#8201;&#177;&#8201;17.286</td><td align="left" colspan="1" rowspan="1">64.080&#8201;&#177;&#8201;14.251</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.510</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Man</td><td align="left" colspan="1" rowspan="1">2496 (48.608%)</td><td align="left" colspan="1" rowspan="1">83 (51.235%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Woman</td><td align="left" colspan="1" rowspan="1">2639 (51.392%)</td><td align="left" colspan="1" rowspan="1">79 (48.765%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Race</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mexican American</td><td align="left" colspan="1" rowspan="1">727 (14.158%)</td><td align="left" colspan="1" rowspan="1">11 (6.790%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Other Hispanic</td><td align="left" colspan="1" rowspan="1">516 (10.049%)</td><td align="left" colspan="1" rowspan="1">12 (7.407%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Non-Hispanic White</td><td align="left" colspan="1" rowspan="1">2197 (42.785%)</td><td align="left" colspan="1" rowspan="1">83 (51.235%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Non-Hispanic Black</td><td align="left" colspan="1" rowspan="1">1074 (20.915%)</td><td align="left" colspan="1" rowspan="1">45 (27.778%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Other Race</td><td align="left" colspan="1" rowspan="1">621 (12.093%)</td><td align="left" colspan="1" rowspan="1">11 (6.790%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">High blood pressure</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">1776 (34.586%)</td><td align="left" colspan="1" rowspan="1">123 (75.926%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">3350 (65.239%)</td><td align="left" colspan="1" rowspan="1">39 (24.074%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">9 (0.175%)</td><td align="left" colspan="1" rowspan="1">0 (0.00%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">High cholesterol level</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">1616 (31.470%)</td><td align="left" colspan="1" rowspan="1">94 (58.025%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">2935 (57.157%)</td><td align="left" colspan="1" rowspan="1">59 (36.420%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">584 (11.373%)</td><td align="left" colspan="1" rowspan="1">9 (5.556%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">562 (10.944%)</td><td align="left" colspan="1" rowspan="1">46 (28.395%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">4446 (86.582%)</td><td align="left" colspan="1" rowspan="1">112 (69.136%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Borderline</td><td align="left" colspan="1" rowspan="1">122 (2.376%)</td><td align="left" colspan="1" rowspan="1">4 (2.469%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">5 (0.097%)</td><td align="left" colspan="1" rowspan="1">0 (0.000%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Coronary heart disease</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">192 (3.739%)</td><td align="left" colspan="1" rowspan="1">29 (17.901%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">4930 (96.008%)</td><td align="left" colspan="1" rowspan="1">131 (80.864%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">13 (0.253%)</td><td align="left" colspan="1" rowspan="1">2 (1.235%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Smoking</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">2211 (43.057%)</td><td align="left" colspan="1" rowspan="1">103 (63.580%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">2923 (56.923%)</td><td align="left" colspan="1" rowspan="1">59 (36.420%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">1 (0.019%)</td><td align="left" colspan="1" rowspan="1">0 (0.000%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Drinking</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">694(13.515%)</td><td align="left" colspan="1" rowspan="1">39 (24.074%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">3305 (64.362%)</td><td align="left" colspan="1" rowspan="1">89 (54.938%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">1136 (22.123%)</td><td align="left" colspan="1" rowspan="1">34 (20.988%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;BMI (kg/m2 )</td><td align="left" colspan="1" rowspan="1">29.092&#8201;&#177;&#8201;6.921</td><td align="left" colspan="1" rowspan="1">29.625&#8201;&#177;&#8201;7.781</td><td char="." align="char" colspan="1" rowspan="1">0.535</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Caffeine (&#956;mol/L)</td><td align="left" colspan="1" rowspan="1">7.689&#8201;&#177;&#8201;10.307</td><td align="left" colspan="1" rowspan="1">8.200&#8201;&#177;&#8201;10.920</td><td char="." align="char" colspan="1" rowspan="1">0.802</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Theophylline (&#956;mol/L)</td><td align="left" colspan="1" rowspan="1">2.995&#8201;&#177;&#8201;10.124</td><td align="left" colspan="1" rowspan="1">2.596&#8201;&#177;&#8201;6.945</td><td char="." align="char" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Paraxanthine (&#956;mol/L)</td><td align="left" colspan="1" rowspan="1">26.612&#8201;&#177;&#8201;29.874</td><td align="left" colspan="1" rowspan="1">19.088&#8201;&#177;&#8201;21.566</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Theobromine (&#956;mol/L)</td><td align="left" colspan="1" rowspan="1">28.384&#8201;&#177;&#8201;40.184</td><td align="left" colspan="1" rowspan="1">21.692&#8201;&#177;&#8201;28.559</td><td char="." align="char" colspan="1" rowspan="1">0.010</td></tr></tbody></table><table-wrap-foot><p>Mean&#8201;&#177;&#8201;SD for continuous variables: <italic toggle="yes">P</italic> value was calculated by logistic regression model.</p><p>% for categorical variables: <italic toggle="yes">P</italic> value was calculated by chi-square test.</p><p>BMI, body mass index.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>The association between urinary caffeine levels and stroke.</title><p id="Par13">The results of the relationship between urinary caffeine levels and stroke are displayed in Table <xref rid="Tab2" ref-type="table">2</xref>. No adjustment and adjustment for different covariates, urinary caffeine levels were consistently not statistically significant with stroke (all <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05). The same results were then obtained by transforming continuous caffeine levels into categorical variables(quartiles) for the four subgroups (all <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05) . Then, stratified analysis by age, sex and race was performed. In racial subgroup analysis, urinary caffeine levels were negatively associated with stroke occurrence in Mexican American (odds ratio [OR]&#8201;=&#8201;0.886, 95% confidence interval [CI]: (0.791, 0.993), <italic toggle="yes">P</italic>&#8201;=&#8201;0.037). When urinary caffeine levels were reduced by one unit(&#956;mol/L), the incidence of stroke was reduced by 11.4%. The findings in other subgroups revealed no conclusive link between urine caffeine metabolites and stroke (all <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05). Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref>A displays the smooth curve fittings of the relationship between urine caffeine levels and the incidence of stroke.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>The association between urinary caffeine levels (&#956;mol/L) and stroke.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Model 1 <italic toggle="yes">OR</italic> (95% <italic toggle="yes">CI</italic>) <italic toggle="yes">P</italic> value</th><th align="left" colspan="1" rowspan="1">Model 2 <italic toggle="yes">OR</italic> (95% <italic toggle="yes">CI</italic>) <italic toggle="yes">P</italic> value</th><th align="left" colspan="1" rowspan="1">Model 3 <italic toggle="yes">OR</italic> (95% <italic toggle="yes">CI</italic>) <italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Caffeine (&#956;mol/L)</td><td align="left" colspan="1" rowspan="1">1.004 (0.991, 1.018) 0.534</td><td align="left" colspan="1" rowspan="1">0.999 (0.984, 1.013) 0.847</td><td align="left" colspan="1" rowspan="1">0.996 (0.981, 1.011) 0.606</td></tr><tr><td align="left" colspan="4" rowspan="1">Caffeine categories</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q1</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">Reference</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q2</td><td align="left" colspan="1" rowspan="1">0.799 (0.515, 1.240) 0.316</td><td align="left" colspan="1" rowspan="1">0.780 (0.496, 1.224) 0.280</td><td align="left" colspan="1" rowspan="1">0.758 (0.478, 1.202) 0.239</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q3</td><td align="left" colspan="1" rowspan="1">0.757 (0.485, 1.183) 0.222</td><td align="left" colspan="1" rowspan="1">0.713 (0.450, 1.129) 0.149</td><td align="left" colspan="1" rowspan="1">0.645 (0.402, 1.035) 0.069</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q4</td><td align="left" colspan="1" rowspan="1">0.948 (0.622, 1.443) 0.802</td><td align="left" colspan="1" rowspan="1">0.816 (0.526, 1.265) 0.363</td><td align="left" colspan="1" rowspan="1">0.747 (0.475, 1.175) 0.207</td></tr><tr><td align="left" colspan="4" rowspan="1">Age categories</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;20&#8211;34</td><td align="left" colspan="1" rowspan="1">1.000 (0.900, 1.112) 0.996</td><td align="left" colspan="1" rowspan="1">0.993 (0.892, 1.105) 0.894</td><td align="left" colspan="1" rowspan="1">0.998 (0.883, 1.128) 0.973</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;35&#8211;49</td><td align="left" colspan="1" rowspan="1">0.991 (0.943, 1.042) 0.722</td><td align="left" colspan="1" rowspan="1">0.993 (0.943, 1.045) 0.782</td><td align="left" colspan="1" rowspan="1">0.994 (0.946, 1.044) 0.808</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;50&#8211;64</td><td align="left" colspan="1" rowspan="1">0.990 (0.962, 1.019) 0.495</td><td align="left" colspan="1" rowspan="1">0.989 (0.960, 1.019) 0.468</td><td align="left" colspan="1" rowspan="1">0.984 (0.953, 1.016) 0.311</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;65&#8211;80</td><td align="left" colspan="1" rowspan="1">1.000 (0.982, 1.017) 0.965</td><td align="left" colspan="1" rowspan="1">1.001 (0.983, 1.019) 0.941</td><td align="left" colspan="1" rowspan="1">1.001 (0.982, 1.020) 0.950</td></tr><tr><td align="left" colspan="4" rowspan="1">Sex</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Men</td><td align="left" colspan="1" rowspan="1">1.000 (0.977, 1.022) 0.970</td><td align="left" colspan="1" rowspan="1">0.990 (0.966, 1.014) 0.417</td><td align="left" colspan="1" rowspan="1">0.985 (0.961, 1.010) 0.244</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Women</td><td align="left" colspan="1" rowspan="1">1.008 (0.991, 1.025) 0.365</td><td align="left" colspan="1" rowspan="1">1.003 (0.986, 1.021) 0.717</td><td align="left" colspan="1" rowspan="1">1.002 (0.983, 1.022) 0.838</td></tr><tr><td align="left" colspan="4" rowspan="1">Race</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mexican American</td><td align="left" colspan="1" rowspan="1">0.971 (0.889, 1.060) 0.509</td><td align="left" colspan="1" rowspan="1">0.952 (0.872, 1.038) 0.264</td><td align="left" colspan="1" rowspan="1">0.886 (0.791, 0.993) 0.037</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Other Hispanic</td><td align="left" colspan="1" rowspan="1">1.022 (0.971, 1.076) 0.396</td><td align="left" colspan="1" rowspan="1">1.007 (0.951, 1.065) 0.820</td><td align="left" colspan="1" rowspan="1">0.998 (0.935, 1.066) 0.959</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Non-Hispanic White</td><td align="left" colspan="1" rowspan="1">1.010 (0.994, 1.025) 0.210</td><td align="left" colspan="1" rowspan="1">1.006 (0.991, 1.022) 0.429</td><td align="left" colspan="1" rowspan="1">1.005 (0.988, 1.022) 0.594</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Non-Hispanic Black</td><td align="left" colspan="1" rowspan="1">0.955 (0.899, 1.014) 0.132</td><td align="left" colspan="1" rowspan="1">0.941 (0.885, 1.001) 0.054</td><td align="left" colspan="1" rowspan="1">0.944 (0.887, 1.004) 0.065</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Other Race</td><td align="left" colspan="1" rowspan="1">1.017 (0.960, 1.078) 0.565</td><td align="left" colspan="1" rowspan="1">1.020 (0.956, 1.088) 0.556</td><td align="left" colspan="1" rowspan="1">1.022 (0.949, 1.099) 0.569</td></tr></tbody></table><table-wrap-foot><p><bold>Model 1</bold>: The covariates were not adjusted.</p><p><bold>Model 2</bold>: The&#160;age, sex,&#160;and race&#160;of&#160;the participants&#160;were adjusted.</p><p><bold>Model 3</bold>: The&#160;age, sex, race, high blood pressure, high cholesterol level, diabetes, coronary heart disease, smoking, drinking, BMI of&#160;participants&#160;were adjusted.</p></table-wrap-foot></table-wrap><fig id="Fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Smooth curve fittings of the association between urinary caffeine and caffeine metabolite levels (&#956;mol/L) and stroke incidence. The red line represents the smoothed curve fitting between caffeine and caffeine metabolite and stroke. The blue line represents its 95% confidence interval. Sex, age, and race, high blood pressure, high cholesterol level, diabetes, coronary heart disease, smoking, drinking, BMI of&#160;participants&#160;were adjusted.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="41598_2023_39126_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec12"><title>The association between urinary caffeine metabolites levels and stroke.</title><p id="Par14">The results of the relationship between urinary caffeine metabolites levels and stroke are displayed in Table <xref rid="Tab3" ref-type="table">3</xref>. No adjustment and adjustment for different covariates, urinary theophylline and theobromine levels were consistently not statistically significant with stroke (all P&#8201;&gt;&#8201;0.05). Then, conversion of continuous urinary theophylline and theobromine levels into categorical variables (quartiles). In Model 1, stroke incidence was reduced in the highest urinary theophylline (OR&#8201;=&#8201;0.574, 95% CI (0.363, 0.907), <italic toggle="yes">P</italic>&#8201;=&#8201;0.017) and theobromine (OR&#8201;=&#8201;0.609, 95% CI (0.386, 0.960), <italic toggle="yes">P</italic>&#8201;=&#8201;0.033) group compared to the lowest group. After adjusting for covariates, urinary theophylline and theobromine levels were not statistically significant with stroke incidence. Smooth curve fittings of the association between urinary theophylline and theobromine levels and stroke incidence are shown in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B,C.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>The association between urinary caffeine metabolites levels (&#956;mol/L) and stroke.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Model 1 <italic toggle="yes">OR</italic> (95% <italic toggle="yes">CI</italic>) <italic toggle="yes">P</italic> value</th><th align="left" colspan="1" rowspan="1">Model 2 <italic toggle="yes">OR</italic> (95% <italic toggle="yes">CI</italic>) <italic toggle="yes">P</italic> value</th><th align="left" colspan="1" rowspan="1">Model 3 <italic toggle="yes">OR</italic> (95% <italic toggle="yes">CI</italic>) <italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Theophylline (&#956;mol/L)</td><td align="left" colspan="1" rowspan="1">0.981 (0.931, 1.033) 0.465</td><td align="left" colspan="1" rowspan="1">0.991 (0.955, 1.028) 0.626</td><td align="left" colspan="1" rowspan="1">0.994 (0.958, 1.032) 0.767</td></tr><tr><td align="left" colspan="4" rowspan="1">Theophylline categories</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q1</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">Reference</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q2</td><td align="left" colspan="1" rowspan="1">0.889 (0.593, 1.335) 0.571</td><td align="left" colspan="1" rowspan="1">0.900 (0.592, 1.367) 0.620</td><td align="left" colspan="1" rowspan="1">0.886 (0.578, 1.357) 0.577</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q3</td><td align="left" colspan="1" rowspan="1">0.672 (0.434, 1.041) 0.075</td><td align="left" colspan="1" rowspan="1">0.704 (0.449, 1.105) 0.127</td><td align="left" colspan="1" rowspan="1">0.678 (0.427, 1.075) 0.099</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q4</td><td align="left" colspan="1" rowspan="1">0.574 (0.363, 0.907) 0.017</td><td align="left" colspan="1" rowspan="1">0.635 (0.395, 1.021) 0.061</td><td align="left" colspan="1" rowspan="1">0.632 (0.388, 1.029) 0.065</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Paraxanthine (&#956;mol/L)</td><td align="left" colspan="1" rowspan="1">0.988 (0.981, 0.995) 0.001</td><td align="left" colspan="1" rowspan="1">0.991 (0.984, 0.998) 0.017</td><td align="left" colspan="1" rowspan="1">0.991 (0.984, 0.999) 0.027</td></tr><tr><td align="left" colspan="4" rowspan="1">Paraxanthine categories</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q1</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">Reference</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q2</td><td align="left" colspan="1" rowspan="1">0.870 (0.584, 1.269) 0.492</td><td align="left" colspan="1" rowspan="1">0.844 (0.559, 1.273) 0.419</td><td align="left" colspan="1" rowspan="1">0.855 (0.562, 1.301) 0.239</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q3</td><td align="left" colspan="1" rowspan="1">0.631 (0.410, 0.973) 0.037</td><td align="left" colspan="1" rowspan="1">0.672 (0.430, 1.048) 0.080</td><td align="left" colspan="1" rowspan="1">0.658 (0.417, 1.038) 0.069</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q4</td><td align="left" colspan="1" rowspan="1">0.470 (0.292, 0.755) 0.002</td><td align="left" colspan="1" rowspan="1">0.549 (0.336, 0.895) 0.016</td><td align="left" colspan="1" rowspan="1">0.563 (0.341, 0.929) 0.025</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Theobromine (&#956;mol/L)</td><td align="left" colspan="1" rowspan="1">0.994 (0.998,1.000) 0.035</td><td align="left" colspan="1" rowspan="1">0.996 (0.990, 1.001) 0.131</td><td align="left" colspan="1" rowspan="1">0.997 (0.992, 1.002) 0.270</td></tr><tr><td align="left" colspan="4" rowspan="1">Theobromine categories</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q1</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">Reference</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q2</td><td align="left" colspan="1" rowspan="1">0.874 (0.578, 1.320) 0.522</td><td align="left" colspan="1" rowspan="1">0.943 (0.617, 1.440) 0.785</td><td align="left" colspan="1" rowspan="1">0.928 (0.602, 1.429) 0.733</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q3</td><td align="left" colspan="1" rowspan="1">0.729 (0.473, 1.123) 0.152</td><td align="left" colspan="1" rowspan="1">0.826 (0.528, 1.294) 0.405</td><td align="left" colspan="1" rowspan="1">0.836 (0.529, 1.320) 0.441</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Q4</td><td align="left" colspan="1" rowspan="1">0.609 (0.386, 0.960) 0.033</td><td align="left" colspan="1" rowspan="1">0.725 (0.452, 1.163) 0.183</td><td align="left" colspan="1" rowspan="1">0.811 (0.501, 1.313) 0.393</td></tr></tbody></table><table-wrap-foot><p><bold>Model 1:</bold> The covariates were not adjusted.</p><p><bold>Model 2:</bold> The&#160;age, sex,&#160;and race&#160;of&#160;the participants&#160;were adjusted.</p><p><bold>Model 3:</bold> The&#160;age, sex, race, high blood pressure, high cholesterol level, diabetes, coronary heart disease, smoking, drinking, BMI of&#160;participants&#160;were adjusted.</p></table-wrap-foot></table-wrap></p><p id="Par15">Model 1 showed that increased levels of urinary paraxanthine levels were associated with a decreased incidence of stroke (OR&#8201;=&#8201;0.988, 95% CI (0.981, 0.995), <italic toggle="yes">P</italic>&#8201;=&#8201;0.001). Model 2 also showed a significant correlation between urinary paraxanthine levels and stroke incidence after adjusting for covariates (OR&#8201;=&#8201;0.991, 95% CI (0.984, 0.998), <italic toggle="yes">P</italic>&#8201;=&#8201;0.017). In Model 3,&#160;when age, sex, race, high blood pressure, high cholesterol level, diabetes, coronary heart disease, smoking, drinking, BMI of&#160;participants were adjusted, the same significant correlation was shown (OR&#8201;=&#8201;0.991, 95% CI (0.984, 0.999), <italic toggle="yes">P</italic>&#8201;=&#8201;0.027). For multiple regression analysis, we further transformed urinary paraxanthine levels from a continuous variable to a categorical variable (four categories). In the second highest urinary paraxanthine levels group(Q2), urinary paraxanthine levels was not statistically significant with stroke incidence, with or without adjustment for covariates. In the third highest urinary paraxanthine levels group(Q3), urinary paraxanthine levels were negatively associated with a reduction in stroke incidence in Model 1(OR&#8201;=&#8201;0.631, 95% CI (0.410, 0.973), <italic toggle="yes">P</italic>&#8201;=&#8201;0.037), but not statistically significant in the other models(all <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05). In the unadjusted covariate models, the highest urinary paraxanthine levels group(Q4) was associated with a reduced incidence of stroke compared with the lowest levels group (OR&#8201;=&#8201;0.470, 95% CI (0.292, 0.755), <italic toggle="yes">P</italic>&#8201;=&#8201;0.002). When adjusting for different covariates, this correlation was still present in Models 2(OR&#8201;=&#8201;0.549, 95% CI (0.336, 0.895), <italic toggle="yes">P</italic>&#8201;=&#8201;0.016) and Models 3(OR&#8201;=&#8201;0.563, 95% CI (0.341, 0.929), <italic toggle="yes">P</italic>&#8201;=&#8201;0.025). After adjusting for a number of covariates, the highesturinary paraxanthine levels group(Q4) had 43.7% fewer strokes than the lowest level group. Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref>D displays the smooth curve fittings of the relationship between urine paraxanthine levels and the incidence of stroke.</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par16">After analyzing the data from a large sample from a 6-year cross-sectional study, we observed that urinary caffeine levels were negatively associated with stroke occurrence in Mexican American, but no correlation in other populations. In addition, urinary paraxanthine levels were negatively associated with the incidence of stroke. Few prior long-term population-based investigations, to our knowledge, have looked at the relationship between standardized measurements of urine caffeine and caffeine metabolites with stroke. Our findings not only provide objective evidence for clinical and basic research, but also have implications for the identification and intervention of stroke risk factors.</p><p id="Par17">Previous studies on NHANES data explored the relationship between stroke and caffeine consumption at the coffee consumption level<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. They concluded that an increase in daily coffee consumption was associated with a decrease in stroke incidence. And some studies have shown that coffee consumption is safe and does not increase the risk of death<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. We considered the diversity of sources of caffeine, with some variation in the types of caffeine-containing foods, ingredients and preparation processes. And self-reported caffeine consumption is not sufficiently accurate, which leaves a large margin of error in the estimation of caffeine content, which is difficult to estimate<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup>. Caffeine has a half-life of 2.5&#8211;4.5&#160;h in humans<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>, so after 9&#160;h of fasting, the difference in caffeine levels in the samples will be further reduced, and therefore the effect of differences in the timing and frequency and amount of final caffeine consumption on the levels of caffeine and its metabolites in urine will be further reduced. Therefore, our study starts from a relatively stable urine sample to clarify the relationship between caffeine and its metabolites and stroke by analysing the levels of caffeine and its metabolites in urine at fixed time points. Our findings are consistent with those of previous studies and further demonstrate the reliability of our research methods. However, a multicenter case-crossover study showed that the relative risk (RR) of stroke within 1&#160;h of coffee consumption was 2.0 (RR&#8201;=&#8201;2.0, 95% CI (1.4&#8211;2.8), <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), which differed from our findings<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. This difference can be attributed to several factors. First, the study compared each participant&#8217;s coffee consumption in the hour before stroke symptoms with his or her usual frequency of consumption in the previous year, which differed somewhat from the metabolic cycle of caffeine. Second, coffee consumption is not a good proxy for caffeine intake because of the different coffee prices and types. Self-reported caffeine intake has been found to be weakly correlated with measured caffeine levels, according to several studies<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup>, which can be attributed to the influence of the numerous components listed above.</p><p id="Par18">We showed in this extensive cross-sectional investigation that urine caffeine levels were negatively correlated with the incidence of stroke among Mexican Americans, while there was no association in other populations. This may be due to differences in the incidence of stroke by race<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. In addition, there are some differences in the dietary habits of different races, where food intake is accompanied by not only caffeine but also other substances, which may influence the occurrence of a stroke. Previous studies have found that CYP1A2 is responsible for over 90% of caffeine me-tabolism<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Individuals with genotype AA are extensive metabolizers of caffeine, those with genotype AC are in-termediate metabolizers of caffeine, and those with genotype CC are low metabolizers of caffeine<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Several studies have shown that CYP1A2 variants differ in different ethnic groups<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. However, there are no relevant studies on CYP1A2 variants in Mexican-Americans. We hope that based on our findings, more scholars will conduct more in-depth studies on the polymorphisms of CYP1A2 in different ethnic groups in the future. A study of a Chinese population, showed that Individuals with CYP1A2 rs762551 C was associated with a lower risk of stroke than that of allele A<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. In individuals with the CYP1A2 rs762551 AC&#8201;+&#8201;CC genotype, coffee consumption was associated with lower odds of hypertension<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. Since hypertension is CYP1A2 variants risk factor for stroke, the study suggests that CYP1A2 variants may be indirectly associated with the development of stroke. The specific mechanisms that link CYP1A2 variants to stroke occurrence still require further in-depth study in the future. Several studies showing that sex-specific activity and expression of the P450 1A2 (CYP1A2) gene were related to caffeine metabolism<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR38">38</xref>&#8211;<xref ref-type="bibr" rid="CR40">40</xref></sup>. A study of ischemic stroke involving 270 (55%) male and 229 (45%) female participants, no sex differences in the severity of the stroke, stroke subtype, or infarct size and location were reported. However, the results showed a higher mortality rate in female participants<sup><xref ref-type="bibr" rid="CR41">41</xref>&#8211;<xref ref-type="bibr" rid="CR43">43</xref></sup>. However, no sex-related differences were observed in our study for the time being. More high-quality randomised controlled studies with large sample sizes are needed in the future to investigate gender differences in stroke risk factors.</p><p id="Par19">Additionally, the incidence of stroke had a negative relationship with urine paraxanthine levels. Some findings may explain our results. First, caffeine, which is an adenosine receptor antagonist, has been reported to exert neuroprotective effects. It attenuates dopaminergic toxicity and decreases inflammation by up regulating the A1 receptors<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Second, caffeine consumption was found to modulate stroke risk factors such as blood glucose and lipid levels<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR45">45</xref></sup>. This result indirectly proves that caffeine intake plays a crucial role in reducing stroke occurrence. Third, endothelial cell injury is an&#160;important&#160;cause&#160;of arterial thrombosis. Caffeine has antioxidant effects and can scavenge reactive oxygen species, especially -OH<sup><xref ref-type="bibr" rid="CR46">46</xref>,<xref ref-type="bibr" rid="CR47">47</xref></sup>. These effects could prevent endothelial cell damage, thus reducing the incidence of stroke. Fourth, habitual caffeine intake could increase sympathetic nerve activity, circulating catecholamines<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>, and arterial blood pressure<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>. This could lead to an increase in the cardiovascular reserve to maintain arterial blood pressure and enhance the tolerance of the central nervous system to the insufficient blood supply, which helps reduce the occurrence of ischemic stroke. In addition, foods containing caffeine may contain various other chemicals. For instance, tea polyphenols, catechin polymers, tea polysaccharides, and other components, such as chlorogenic acid and phenolic compounds, are found in coffee<sup><xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup>. These compounds may have anti-inflammatory, anti-thrombotic, and anti-inflammatory properties in addition to controlling metabolism, reducing blood sugar and cholesterol levels, enhancing gut flora, increasing endothelial function, and promoting antioxidant activity<sup><xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR53">53</xref></sup>. Finally, a study showed that increased caffeine intake reduced DNA methylation levels, which were positively correlated with biological age, a stronger risk factor for stroke than age<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. This finding further indicated that increased caffeine intake may lower biological age, thus reducing the occurrence of stroke. However, based on the above-mentioned speculations and findings, the exact relationship between caffeine and caffeine metabolites and stroke cannot be determined, and more relevant studies are needed.</p><p id="Par20">Our research advantage lies mainly in the following several areas. First, it is a large sample analysis from NHANES data, which may minimize bias owing to insufficient sample size. Second, data were stratified by sex, age, and race and the sample in the current study was analyzed using multiple regression analysis after multiple confounders were taken into account, including age, sex, race, high blood pressure, high cholesterol, diabetes, coronary heart disease, smoking, drinking, and BMI of participants. We examined a number of risk factors that are frequently linked to stroke, which may offer more reliable proof of a connection between caffeine and caffeine metabolites in urine and the incidence of stroke Thirdly, to avoid recall bias, misclassification, and kind and preparation of food, our exposure variables were evaluated by urine levels of caffeine and caffeine metabolites rather than self-reported caffeine-containing food intake. There are a few restrictions on this study. Firstly, because this was a cross-sectional study, it is not possible to conclude that caffeine metabolites cause stroke based solely on the results shown above. Further longitudinal studies are required to address this question. Second, the participants in this study were mainly from the U.S., which is not representative of the global population. Thus, more multi-regional and multi-center studies are needed to further investigate the relationship between stroke incidence and caffeine metabolite levels. Third, as the NHANES database does not distinguish between types of stroke, our study can only suggest an association between caffeine and its metabolites and stroke, and does not clarify whether the stroke was haemorrhagic or ischaemic. Finally, due to the way the NHANES data were stratified and the inherently lower incidence of stroke, the number of participants in the stroke group was smaller than in the control group, which may have caused some bias in the study results. However, the development of different models and the analysis of multiple covariates have led to more reliable results on the relationship between caffeine and its metabolites and stroke. More accurate randomized controlled trials are required to validate the results of this study.</p></sec><sec id="Sec14"><title>Conclusions</title><p id="Par21">In this study, we showed a negative link between urine paraxanthine levels and the risk of stroke. Meanwhile, urinary caffeine levels were negatively associated with the incidence of stroke in Mexican Americans, but no correlation in other populations. Our findings may have predictive and diagnostic implications in clinical practice. Further extensive prospective investigations are still needed to validate our conclusions.</p></sec></body><back><fn-group><fn><p><bold>Publisher's note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Jinming Fan and Yajun Yuan.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We acknowledge the data from the National Health and Nutrition Examination Survey (NHANES). We also acknowledge assistance from proof-readers and editors.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization, J.F. and Y.Y.; methodology, X.Z.; software, W.L.; validation, J.F., Y.Y. and W.M.; formal analysis, W.W.; investigation, W.W.; resources, B.Z.; data curation, J.F.; writing&#8212;original draft preparation, J.F. and Y.Y.; writing&#8212;review and editing, X.Z., J.G. and B.Z.; visualization, W.L.; supervision, B.Z.; project administration, J.G.; funding acquisition, B.Z. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was funded by the National Natural Science Foundation of China grant number 82102164.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The original data were accessed from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/nhanes/about_nhanes">https://www.cdc.gov/nchs/nhanes/about_nhanes</ext-link>.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par22">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>W</given-names></name><name name-style="western"><surname>Qiang</surname><given-names>T</given-names></name><name name-style="western"><surname>Chai</surname><given-names>L</given-names></name><name name-style="western"><surname>Liang</surname><given-names>T</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>James</surname><given-names>TD</given-names></name></person-group><article-title>Simultaneous tracking of autophagy and oxidative stress during stroke with an ICT-TBET integrated ratiometric two-photon platform</article-title><source>Chem. Sci.</source><year>2022</year><volume>13</volume><issue>18</issue><fpage>5363</fpage><lpage>5373</lpage><pub-id pub-id-type="doi">10.1039/d1sc06805a</pub-id><pub-id pub-id-type="pmid">35655567</pub-id><pub-id pub-id-type="pmcid">PMC9093177</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>SW</given-names></name><name name-style="western"><surname>Chi</surname><given-names>WC</given-names></name><name name-style="western"><surname>Chang</surname><given-names>KH</given-names></name><etal/></person-group><article-title>World health organization disability assessment schedule 2.0 as an objective assessment tool for predicting return to work after a stroke</article-title><source>Disabil. Rehabil.</source><year>2018</year><volume>40</volume><issue>21</issue><fpage>2592</fpage><lpage>2597</lpage><pub-id pub-id-type="doi">10.1080/09638288.2017.1342280</pub-id><pub-id pub-id-type="pmid">28657351</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feigin</surname><given-names>VL</given-names></name><name name-style="western"><surname>Stark</surname><given-names>BA</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>CO</given-names></name><name name-style="western"><surname>Roth</surname><given-names>GA</given-names></name><name name-style="western"><surname>Bisignano</surname><given-names>C</given-names></name><name name-style="western"><surname>Abady</surname><given-names>GG</given-names></name><name name-style="western"><surname>Abbasifard</surname><given-names>M</given-names></name><name name-style="western"><surname>Abbasi-Kangevari</surname><given-names>M</given-names></name><name name-style="western"><surname>Abd-Allah</surname><given-names>F</given-names></name><name name-style="western"><surname>Abedi</surname><given-names>V</given-names></name><name name-style="western"><surname>Abualhasan</surname><given-names>A</given-names></name></person-group><article-title>Global, regional, and national burden of stroke and its risk factors, 1990&#8211;2019: A systematic analysis for the global burden of disease study 2019</article-title><source>Lancet Neurol.</source><year>2021</year><volume>20</volume><issue>10</issue><fpage>795</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00252-0</pub-id><pub-id pub-id-type="pmid">34487721</pub-id><pub-id pub-id-type="pmcid">PMC8443449</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mai</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X</given-names></name></person-group><article-title>Risk factors for stroke based on the national health and nutrition examination survey</article-title><source>J. Nutr. Health Aging</source><year>2020</year><volume>24</volume><issue>7</issue><fpage>791</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1007/s12603-020-1430-4</pub-id><pub-id pub-id-type="pmid">32744577</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aigner</surname><given-names>A</given-names></name><name name-style="western"><surname>Grittner</surname><given-names>U</given-names></name><name name-style="western"><surname>Rolfs</surname><given-names>A</given-names></name><name name-style="western"><surname>Norrving</surname><given-names>B</given-names></name><name name-style="western"><surname>Siegerink</surname><given-names>B</given-names></name><name name-style="western"><surname>Busch</surname><given-names>MA</given-names></name></person-group><article-title>Contribution of established stroke risk factors to the burden of stroke in young adults</article-title><source>Stroke</source><year>2017</year><volume>48</volume><issue>7</issue><fpage>1744</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.117.016599</pub-id><pub-id pub-id-type="pmid">28619986</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aono</surname><given-names>T</given-names></name><name name-style="western"><surname>Shinya</surname><given-names>Y</given-names></name><name name-style="western"><surname>Miyawaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>T</given-names></name><name name-style="western"><surname>Kumagai</surname><given-names>I</given-names></name><name name-style="western"><surname>Takenobu</surname><given-names>A</given-names></name><name name-style="western"><surname>Shin</surname><given-names>M</given-names></name><name name-style="western"><surname>Saito</surname><given-names>N</given-names></name><name name-style="western"><surname>Teraoka</surname><given-names>A</given-names></name></person-group><article-title>Changes in the risk of stroke in dialysis patients: A retrospective analysis over the last 40 years</article-title><source>Toxins (Basel)</source><year>2021</year><volume>13</volume><issue>5</issue><fpage>350</fpage><pub-id pub-id-type="doi">10.3390/toxins13050350</pub-id><pub-id pub-id-type="pmid">34068165</pub-id><pub-id pub-id-type="pmcid">PMC8170903</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heckman</surname><given-names>MA</given-names></name><name name-style="western"><surname>Weil</surname><given-names>J</given-names></name><name name-style="western"><surname>De Mejia</surname><given-names>EG</given-names></name></person-group><article-title>Caffeine (1, 3, 7-trimethylxanthine) in foods: A comprehensive review on consumption, functionality, safety, and regulatory matters</article-title><source>J. Food Sci.</source><year>2010</year><volume>75</volume><fpage>77</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3841.2010.01561.x</pub-id><pub-id pub-id-type="pmid">20492310</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>D</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>C</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>D</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>V</given-names></name><name name-style="western"><surname>Nottingham</surname><given-names>K</given-names></name><name name-style="western"><surname>Dickerson</surname><given-names>B</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>M</given-names></name><name name-style="western"><surname>Ko</surname><given-names>J</given-names></name><name name-style="western"><surname>Faries</surname><given-names>M</given-names></name><name name-style="western"><surname>Kephart</surname><given-names>W</given-names></name><name name-style="western"><surname>Purpura</surname><given-names>M</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>R</given-names></name><name name-style="western"><surname>Wells</surname><given-names>SD</given-names></name><name name-style="western"><surname>Sowinski</surname><given-names>R</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Kreider</surname><given-names>RB</given-names></name></person-group><article-title>Dose-response of paraxanthine on cognitive function: A double blind, placebo controlled, crossover trial</article-title><source>Nutrients</source><year>2021</year><volume>13</volume><issue>12</issue><fpage>4478</fpage><pub-id pub-id-type="doi">10.3390/nu13124478</pub-id><pub-id pub-id-type="pmid">34960030</pub-id><pub-id pub-id-type="pmcid">PMC8708375</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martyn</surname><given-names>D</given-names></name><name name-style="western"><surname>Lau</surname><given-names>A</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>P</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A</given-names></name></person-group><article-title>Temporal patterns of caffeine intake in the United States</article-title><source>Food Chem Toxicol.</source><year>2018</year><volume>111</volume><fpage>71</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2017.10.059</pub-id><pub-id pub-id-type="pmid">29109041</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Associations between urinary caffeine and caffeine metabolites and cognitive function in older adults</article-title><source>Nutr. Neurosci.</source><year>2022</year><pub-id pub-id-type="doi">10.1080/1028415X.2022.2071809</pub-id><pub-id pub-id-type="pmid">35715983</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>C</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name><etal/></person-group><article-title>Association between the prognostic nutritional index and severe headache or migraine: A population-based study</article-title><source>Nutr. Neurosci.</source><year>2022</year><pub-id pub-id-type="doi">10.1080/1028415X.2022.2143958</pub-id><pub-id pub-id-type="pmid">36384436</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zwilling</surname><given-names>M</given-names></name><name name-style="western"><surname>Theiss</surname><given-names>C</given-names></name><name name-style="western"><surname>Matschke</surname><given-names>V</given-names></name></person-group><article-title>Caffeine and NAD+ improve motor neural integrity of dissociated wobbler cells in vitro</article-title><source>Antioxidants</source><year>2020</year><volume>9</volume><fpage>460</fpage><pub-id pub-id-type="doi">10.3390/antiox9060460</pub-id><pub-id pub-id-type="pmid">32471290</pub-id><pub-id pub-id-type="pmcid">PMC7346375</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Lin</surname><given-names>F</given-names></name><name name-style="western"><surname>Xin</surname><given-names>N</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>P</given-names></name></person-group><article-title>Association of coffee, tea, and caffeine consumption with all-cause risk and specific mortality for cardiovascular disease patients</article-title><source>Front Nutr.</source><year>2022</year><volume>9</volume><fpage>842856</fpage><pub-id pub-id-type="doi">10.3389/fnut.2022.842856</pub-id><pub-id pub-id-type="pmid">35811963</pub-id><pub-id pub-id-type="pmcid">PMC9261910</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Gelder</surname><given-names>BM</given-names></name><name name-style="western"><surname>Buijsse</surname><given-names>B</given-names></name><name name-style="western"><surname>Tijhuis</surname><given-names>M</given-names></name><name name-style="western"><surname>Kalmijn</surname><given-names>S</given-names></name><name name-style="western"><surname>Giampaoli</surname><given-names>S</given-names></name><name name-style="western"><surname>Nissinen</surname><given-names>A</given-names></name><name name-style="western"><surname>Kromhout</surname><given-names>D</given-names></name></person-group><article-title>Coffee consumption is inversely associated with cognitive decline in elderly European men</article-title><source>The FINE Study Eur. J. Clin. Nutr</source><year>2006</year><volume>61</volume><fpage>226</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1038/sj.ejcn.1602495</pub-id><pub-id pub-id-type="pmid">16929246</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'Keefe</surname><given-names>JH</given-names></name><name name-style="western"><surname>DiNicolantonio</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Lavie</surname><given-names>CJ</given-names></name></person-group><article-title>Coffee for cardioprotection and longevity</article-title><source>Prog Cardiovasc Dis.</source><year>2018</year><volume>61</volume><issue>1</issue><fpage>38</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.pcad.2018.02.002</pub-id><pub-id pub-id-type="pmid">29474816</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Garcia</surname><given-names>E</given-names></name><name name-style="western"><surname>Rodriguez-Artalejo</surname><given-names>F</given-names></name><name name-style="western"><surname>Rexrode</surname><given-names>K</given-names></name><name name-style="western"><surname>Logroscino</surname><given-names>G</given-names></name><name name-style="western"><surname>Hu</surname><given-names>FB</given-names></name><name name-style="western"><surname>Van Dam</surname><given-names>RM</given-names></name></person-group><article-title>Coffee consumption and risk of stroke in women</article-title><source>Circulation</source><year>2009</year><volume>119</volume><fpage>1116</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.826164</pub-id><pub-id pub-id-type="pmid">19221216</pub-id><pub-id pub-id-type="pmcid">PMC2729465</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jee</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SG</given-names></name><name name-style="western"><surname>Bormate</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Jung</surname><given-names>YS</given-names></name></person-group><article-title>Effect of caffeine consumption on the risk for neurological and psychiatric disorders: Sex differences in human</article-title><source>Nutrients</source><year>2020</year><volume>12</volume><issue>10</issue><fpage>3080</fpage><pub-id pub-id-type="doi">10.3390/nu12103080</pub-id><pub-id pub-id-type="pmid">33050315</pub-id><pub-id pub-id-type="pmcid">PMC7601837</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Association of urinary caffeine and caffeine metabolites with cardiovascular disease risk in adults</article-title><source>Nutrition</source><year>2021</year><volume>84</volume><fpage>111121</fpage><pub-id pub-id-type="doi">10.1016/j.nut.2020.111121</pub-id><pub-id pub-id-type="pmid">33515809</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nehlig</surname><given-names>A</given-names></name></person-group><article-title>Interindividual differences in caffeine metabolism and factors driving caffeine consumption</article-title><source>Pharmacol Rev.</source><year>2018</year><volume>70</volume><issue>2</issue><fpage>384</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1124/pr.117.014407</pub-id><pub-id pub-id-type="pmid">29514871</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Curtin LR, Mohadjer LK, Dohrmann SM, Kruszon-Moran D, Mirel LB, Carroll MD, <italic toggle="yes">et al.</italic> National health and nutrition examination survey: sample design, 2007&#8211;2010. Vital Health Stat (2013), 1&#8211;23. Series 2, Data evaluation and methods research<pub-id pub-id-type="pmid">25090039</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glover</surname><given-names>FE</given-names></name><name name-style="western"><surname>Caudle</surname><given-names>WM</given-names></name><name name-style="western"><surname>Del Giudice</surname><given-names>F</given-names></name><etal/></person-group><article-title>The association between caffeine intake and testosterone: NHANES 2013&#8211;2014</article-title><source>Nutr. J.</source><year>2022</year><volume>21</volume><issue>1</issue><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s12937-022-00783-z</pub-id><pub-id pub-id-type="pmid">35578259</pub-id><pub-id pub-id-type="pmcid">PMC9112543</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">U. S. Centers for Disease Control prevention laboratory data overview, national health and nutrition examination survey. [(accessed on 19 March 2020)];&#160;Available online:&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/overviewlab.aspx?BeginYear=2011">https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/overviewlab.aspx?BeginYear=2011</ext-link></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Caffeine and Caffeine Metabolites - Urine Lab Procedure Manual&#160;(June 2020);&#160;Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwn.cdc.gov/nchs/data/nhanes/2013-2014/labmethods/CAFE-H-MET-508.pdf">https://wwwn.cdc.gov/nchs/data/nhanes/2013-2014/labmethods/CAFE-H-MET-508.pdf</ext-link></mixed-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Min</surname><given-names>JY</given-names></name><name name-style="western"><surname>Min</surname><given-names>KB</given-names></name></person-group><article-title>Caffeine and caffeine metabolites in relation to insulin resistance and beta cell function in U.S. adults</article-title><source>Nutrients</source><year>2020</year><volume>12</volume><issue>6</issue><fpage>1783</fpage><pub-id pub-id-type="doi">10.3390/nu12061783</pub-id><pub-id pub-id-type="pmid">32549382</pub-id><pub-id pub-id-type="pmcid">PMC7353167</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liebeskind</surname><given-names>DS</given-names></name><name name-style="western"><surname>Sanossian</surname><given-names>N</given-names></name><name name-style="western"><surname>Fu</surname><given-names>KA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Arab</surname><given-names>L</given-names></name></person-group><article-title>The coffee paradox in stroke: Increased consumption linked with fewer strokes</article-title><source>Nutr. Neurosci.</source><year>2016</year><volume>19</volume><issue>9</issue><fpage>406</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1179/1476830515Y.0000000035</pub-id><pub-id pub-id-type="pmid">26098738</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Estoppey Younes</surname><given-names>S</given-names></name><name name-style="western"><surname>Pruijm</surname><given-names>M</given-names></name><name name-style="western"><surname>Ponte</surname><given-names>B</given-names></name><name name-style="western"><surname>Ackermann</surname><given-names>D</given-names></name><name name-style="western"><surname>Ehret</surname><given-names>G</given-names></name><etal/></person-group><article-title>Relation of 24-hour urinary caffeine and caffeine metabolite excretions with self-reported consumption of coffee and other caffeinated beverages in the general population</article-title><source>Nutr. Metab. (Lond)</source><year>2016</year><volume>13</volume><fpage>81</fpage><pub-id pub-id-type="doi">10.1186/s12986-016-0144-4</pub-id><pub-id pub-id-type="pmid">27891166</pub-id><pub-id pub-id-type="pmcid">PMC5112879</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kahathuduwa</surname><given-names>CN</given-names></name><name name-style="western"><surname>Wakefield</surname><given-names>S</given-names></name><name name-style="western"><surname>West</surname><given-names>BD</given-names></name><name name-style="western"><surname>Blume</surname><given-names>J</given-names></name><name name-style="western"><surname>Dassanayake</surname><given-names>TL</given-names></name><name name-style="western"><surname>Weerasinghe</surname><given-names>VS</given-names></name><name name-style="western"><surname>Mastergeorge</surname><given-names>A</given-names></name></person-group><article-title>Effects of L-theanine-caffeine combination on sustained attention and inhibitory control among children with ADHD: A proof-of-concept neuroimaging RCT</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>13072</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-70037-7</pub-id><pub-id pub-id-type="pmid">32753637</pub-id><pub-id pub-id-type="pmcid">PMC7403383</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shulman</surname><given-names>LM</given-names></name></person-group><article-title>Is there a connection between estrogen and Parkinson's disease?</article-title><source>Parkinsonism Relat Disord.</source><year>2002</year><volume>8</volume><issue>5</issue><fpage>289</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/s1353-8020(02)00014-7</pub-id><pub-id pub-id-type="pmid">15177058</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mostofsky</surname><given-names>E</given-names></name><name name-style="western"><surname>Schlaug</surname><given-names>G</given-names></name><name name-style="western"><surname>Mukamal</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Rosamond</surname><given-names>WD</given-names></name><name name-style="western"><surname>Mittleman</surname><given-names>MA</given-names></name></person-group><article-title>Coffee and acute ischemic stroke onset: The stroke onset study</article-title><source>Neurology</source><year>2010</year><volume>75</volume><issue>18</issue><fpage>1583</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181fb443d</pub-id><pub-id pub-id-type="pmid">20881275</pub-id><pub-id pub-id-type="pmcid">PMC3120108</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>G</given-names></name><name name-style="western"><surname>Lackland</surname><given-names>DT</given-names></name><name name-style="western"><surname>Kleindorfer</surname><given-names>DO</given-names></name><name name-style="western"><surname>Kissela</surname><given-names>BM</given-names></name><name name-style="western"><surname>Moy</surname><given-names>CS</given-names></name><name name-style="western"><surname>Judd</surname><given-names>SE</given-names></name><name name-style="western"><surname>Safford</surname><given-names>MM</given-names></name><name name-style="western"><surname>Cushman</surname><given-names>M</given-names></name><name name-style="western"><surname>Glasser</surname><given-names>SP</given-names></name><name name-style="western"><surname>Howard</surname><given-names>VJ</given-names></name></person-group><article-title>Racial differences in the impact of elevated systolic blood pressure on stroke risk</article-title><source>JAMA Intern. Med.</source><year>2013</year><volume>173</volume><issue>1</issue><fpage>46</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1001/2013.jamainternmed.857</pub-id><pub-id pub-id-type="pmid">23229778</pub-id><pub-id pub-id-type="pmcid">PMC3759226</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaiser</surname><given-names>P</given-names></name><name name-style="western"><surname>Peralta</surname><given-names>CA</given-names></name><name name-style="western"><surname>Kronmal</surname><given-names>R</given-names></name><name name-style="western"><surname>Shlipak</surname><given-names>MG</given-names></name><name name-style="western"><surname>Psaty</surname><given-names>BM</given-names></name><name name-style="western"><surname>Odden</surname><given-names>MC</given-names></name></person-group><article-title>Racial/ethnic heterogeneity in associations of blood pressure and incident cardiovascular disease by functional status in a prospective cohort: The Multi-Ethnic Study of Atherosclerosis</article-title><source>BMJ Open</source><year>2018</year><volume>8</volume><issue>2</issue><fpage>e017746</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2017-017746</pub-id><pub-id pub-id-type="pmid">29476026</pub-id><pub-id pub-id-type="pmcid">PMC5855482</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishii</surname><given-names>M</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>T</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Asai</surname><given-names>S</given-names></name></person-group><article-title>13C-caffeine breath test identifies single nucleotide polymorphisms associated with caffeine metabolism</article-title><source>Drug Metab. Pharmacokinet.</source><year>2020</year><volume>35</volume><issue>3</issue><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.dmpk.2020.03.003</pub-id><pub-id pub-id-type="pmid">32303460</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sachse</surname><given-names>C</given-names></name><name name-style="western"><surname>Brockmoller</surname><given-names>J</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>S</given-names></name><name name-style="western"><surname>Roots</surname><given-names>I</given-names></name></person-group><article-title>Functional significance of a C&#8211;&gt;A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine</article-title><source>Br. J. Clin. Pharmacol.</source><year>1999</year><volume>47</volume><issue>4</issue><fpage>445e9</fpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.1999.00898.x</pub-id><pub-id pub-id-type="pmid">10233211</pub-id><pub-id pub-id-type="pmcid">PMC2014233</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Relling</surname><given-names>MV</given-names></name><name name-style="western"><surname>Lin</surname><given-names>JS</given-names></name><name name-style="western"><surname>Ayers</surname><given-names>GD</given-names></name><name name-style="western"><surname>Evans</surname><given-names>WE</given-names></name></person-group><article-title>Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities</article-title><source>Clin Pharmacol Ther.</source><year>1992</year><volume>52</volume><issue>6</issue><fpage>643</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1038/clpt.1992.203</pub-id><pub-id pub-id-type="pmid">1458773</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>YF</given-names></name><name name-style="western"><surname>Corton</surname><given-names>JC</given-names></name><name name-style="western"><surname>Klaassen</surname><given-names>CD</given-names></name></person-group><article-title>Expression of cytochrome P450 isozyme transcripts and activities in human livers</article-title><source>Xenobiotica</source><year>2021</year><volume>51</volume><issue>3</issue><fpage>279</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1080/00498254.2020.1867929</pub-id><pub-id pub-id-type="pmid">33350342</pub-id><pub-id pub-id-type="pmcid">PMC8215780</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>The influence of CYP1A1 and CYP1A2 polymorphisms on stroke risk in the Chinese population</article-title><source>Lipids Health Dis.</source><year>2020</year><volume>19</volume><issue>1</issue><fpage>221</fpage><pub-id pub-id-type="doi">10.1186/s12944-020-01370-z</pub-id><pub-id pub-id-type="pmid">33046100</pub-id><pub-id pub-id-type="pmcid">PMC7552501</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>CC</given-names></name><name name-style="western"><surname>Tantoh</surname><given-names>DM</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>PH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Liaw</surname><given-names>YP</given-names></name></person-group><article-title>Association between hypertension and coffee drinking based on CYP1A2 rs762551 single nucleotide polymorphism in Taiwanese</article-title><source>Nutr. Metab. (Lond)</source><year>2021</year><volume>18</volume><issue>1</issue><fpage>78</fpage><pub-id pub-id-type="doi">10.1186/s12986-021-00605-9</pub-id><pub-id pub-id-type="pmid">34391463</pub-id><pub-id pub-id-type="pmcid">PMC8364041</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grobbee</surname><given-names>DE</given-names></name><name name-style="western"><surname>Rimm</surname><given-names>EB</given-names></name><name name-style="western"><surname>Giovannucci</surname><given-names>E</given-names></name><name name-style="western"><surname>Colditz</surname><given-names>G</given-names></name><name name-style="western"><surname>Stampfer</surname><given-names>M</given-names></name><name name-style="western"><surname>Willett</surname><given-names>W</given-names></name></person-group><article-title>Coffee, caffeine, and cardiovascular disease in men</article-title><source>N Engl J Med</source><year>1990</year><volume>323</volume><fpage>1026</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1056/NEJM199010113231504</pub-id><pub-id pub-id-type="pmid">2215561</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scandlyn</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>EC</given-names></name><name name-style="western"><surname>Rosengren</surname><given-names>RJ</given-names></name></person-group><article-title>Sex-specific differences in CYP450 isoforms in humans</article-title><source>Expert Opin. Drug Metab. Toxicol.</source><year>2008</year><volume>4</volume><fpage>413</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1517/17425255.4.4.413</pub-id><pub-id pub-id-type="pmid">18524030</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hong</surname><given-names>H</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C-W</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L-W</given-names></name><name name-style="western"><surname>Lyn-Cook</surname><given-names>B</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><name name-style="western"><surname>Ning</surname><given-names>B</given-names></name></person-group><article-title>Sex differences in the expression of drug-metabolizing and transporter genes in human liver</article-title><source>J. Drug Metab. Toxicol.</source><year>2012</year><volume>3</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.4172/2157-7609.1000119</pub-id><pub-id pub-id-type="pmcid">PMC5699760</pub-id><pub-id pub-id-type="pmid">29177108</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jerath</surname><given-names>NU</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>C</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>WD</given-names></name><name name-style="western"><surname>Jerath</surname><given-names>AU</given-names></name><name name-style="western"><surname>Brown</surname><given-names>RD</given-names></name></person-group><article-title>Gender differences in presenting signs and symptoms of acute ischemic stroke: A population-based study</article-title><source>Gend. Med.</source><year>2011</year><volume>8</volume><fpage>312</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.genm.2011.08.001</pub-id><pub-id pub-id-type="pmid">21925968</pub-id><pub-id pub-id-type="pmcid">PMC3324562</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrett</surname><given-names>KM</given-names></name><name name-style="western"><surname>Brott</surname><given-names>TG</given-names></name><name name-style="western"><surname>Brown</surname><given-names>RD</given-names></name><name name-style="western"><surname>Frankel</surname><given-names>MR</given-names></name><name name-style="western"><surname>Worrall</surname><given-names>BB</given-names></name><name name-style="western"><surname>Silliman</surname><given-names>SL</given-names></name><name name-style="western"><surname>Case</surname><given-names>LD</given-names></name><name name-style="western"><surname>Rich</surname><given-names>SS</given-names></name><name name-style="western"><surname>Meschia</surname><given-names>JF</given-names></name></person-group><article-title>Ischemic stroke genetics study group. Sex differences in stroke severity, symptoms, and deficits after first-ever ischemic stroke</article-title><source>J. Stroke Cerebrovasc. Dis.</source><year>2007</year><volume>16</volume><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2006.11.002</pub-id><pub-id pub-id-type="pmid">17689390</pub-id><pub-id pub-id-type="pmcid">PMC1945157</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrea</surname><given-names>RE</given-names></name><name name-style="western"><surname>Beiser</surname><given-names>AS</given-names></name><name name-style="western"><surname>Seshadri</surname><given-names>S</given-names></name><name name-style="western"><surname>Kelly-Hayes</surname><given-names>M</given-names></name><name name-style="western"><surname>Kase</surname><given-names>CS</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>PA</given-names></name></person-group><article-title>Gender differences in stroke incidence and poststroke disability in the Framingham heart study</article-title><source>Stroke</source><year>2009</year><volume>40</volume><fpage>1032</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.108.542894</pub-id><pub-id pub-id-type="pmid">19211484</pub-id><pub-id pub-id-type="pmcid">PMC2676725</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alperet</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Rebello</surname><given-names>SA</given-names></name><name name-style="western"><surname>Khoo</surname><given-names>EY-H</given-names></name><name name-style="western"><surname>Tay</surname><given-names>Z</given-names></name><name name-style="western"><surname>Seah</surname><given-names>SS-Y</given-names></name><name name-style="western"><surname>Tai</surname><given-names>B-C</given-names></name><name name-style="western"><surname>Tai</surname><given-names>E-S</given-names></name><name name-style="western"><surname>Emady-Azar</surname><given-names>S</given-names></name><name name-style="western"><surname>Chou</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Darimont</surname><given-names>C</given-names></name><etal/></person-group><article-title>The effect of coffee consumption on insulin sensitivity and other biological risk factors for type 2 diabetes: A randomized placebo-controlled trial</article-title><source>Am. J. Clin. Nutr.</source><year>2019</year><volume>111</volume><fpage>448</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1093/ajcn/nqz306</pub-id><pub-id pub-id-type="pmid">31891374</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lecoultre</surname><given-names>V</given-names></name><name name-style="western"><surname>Carrel</surname><given-names>G</given-names></name><name name-style="western"><surname>Egli</surname><given-names>L</given-names></name><name name-style="western"><surname>Binnert</surname><given-names>C</given-names></name><name name-style="western"><surname>Boss</surname><given-names>A</given-names></name><name name-style="western"><surname>MacMillan</surname><given-names>EL</given-names></name><etal/></person-group><article-title>Coffee consumption attenuates short-term fructose-induced liver insulin resistance in healthy men</article-title><source>Am. J. Clin. Nutr.</source><year>2013</year><volume>99</volume><issue>2</issue><fpage>268</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.3945/ajcn.113.069526</pub-id><pub-id pub-id-type="pmid">24257718</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S</given-names></name><name name-style="western"><surname>Jung</surname><given-names>S</given-names></name><name name-style="western"><surname>Ko</surname><given-names>K</given-names></name></person-group><article-title>Effects of coffee extracts with different roasting degrees on antioxidant and anti-inflammatory systems in mice</article-title><source>Nutrients</source><year>2018</year><volume>10</volume><issue>3</issue><fpage>363</fpage><pub-id pub-id-type="doi">10.3390/nu10030363</pub-id><pub-id pub-id-type="pmid">29547558</pub-id><pub-id pub-id-type="pmcid">PMC5872781</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varma</surname><given-names>SD</given-names></name><name name-style="western"><surname>Hegde</surname><given-names>KR</given-names></name><name name-style="western"><surname>Kovtun</surname><given-names>S</given-names></name></person-group><article-title>Oxidative stress in lens in vivo: Inhibitory effect of caffeine. A preliminary report</article-title><source>Mol. Vis.</source><year>2010</year><volume>16</volume><fpage>501</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">20352023</pub-id><pub-id pub-id-type="pmcid">PMC2845664</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Izzo</surname><given-names>JL</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Ghosal</surname><given-names>A</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>T</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>RB</given-names></name><name name-style="western"><surname>Jaenike</surname><given-names>JR</given-names></name></person-group><article-title>Age and prior caffeine use alter the cardiovascular and adrenomedullary responses to oral caffeine</article-title><source>Am. J. Cardiol</source><year>1983</year><volume>52</volume><issue>7</issue><fpage>769</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1016/0002-9149(83)90413-7</pub-id><pub-id pub-id-type="pmid">6353897</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Astrup</surname><given-names>A</given-names></name><name name-style="western"><surname>Toubro</surname><given-names>S</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>S</given-names></name><name name-style="western"><surname>Hein</surname><given-names>P</given-names></name><name name-style="western"><surname>Breum</surname><given-names>L</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>J</given-names></name></person-group><article-title>Caffeine: A double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers</article-title><source>Am. J. Clin. Nutr.</source><year>1990</year><volume>51</volume><issue>5</issue><fpage>759</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1093/ajcn/51.5.759</pub-id><pub-id pub-id-type="pmid">2333832</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sudano</surname><given-names>I</given-names></name><name name-style="western"><surname>Spieker</surname><given-names>L</given-names></name><name name-style="western"><surname>Binggeli</surname><given-names>C</given-names></name><name name-style="western"><surname>Ruschitzka</surname><given-names>F</given-names></name><name name-style="western"><surname>L&#252;scher</surname><given-names>TF</given-names></name><name name-style="western"><surname>Noll</surname><given-names>G</given-names></name><name name-style="western"><surname>Corti</surname><given-names>R</given-names></name></person-group><article-title>Coffee blunts mental stress-induced blood pressure increase in habitual but not in nonhabitual coffee drinkers</article-title><source>Hypertension</source><year>2005</year><volume>46</volume><issue>3</issue><fpage>521</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000177448.56745.c7</pub-id><pub-id pub-id-type="pmid">16103273</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farias-Pereira</surname><given-names>R</given-names></name><name name-style="western"><surname>Park</surname><given-names>CS</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y</given-names></name></person-group><article-title>Mechanisms of action of coffee bioactive components on lipid metabolism</article-title><source>Food Sci. Biotechnol.</source><year>2019</year><volume>28</volume><fpage>1287</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1007/s10068-019-00662-0</pub-id><pub-id pub-id-type="pmid">31695927</pub-id><pub-id pub-id-type="pmcid">PMC6811484</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>N</given-names></name><name name-style="western"><surname>Mukhtar</surname><given-names>H</given-names></name></person-group><article-title>Tea polyphenols in promotion of human health</article-title><source>Nutrients</source><year>2018</year><volume>11</volume><fpage>39</fpage><pub-id pub-id-type="doi">10.3390/nu11010039</pub-id><pub-id pub-id-type="pmid">30585192</pub-id><pub-id pub-id-type="pmcid">PMC6356332</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Su</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>W</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><etal/></person-group><article-title>Chlorogenic acids in cardiovascular disease: A review of dietary consumption, pharmacology, and pharmacokinetics</article-title><source>J. Agric. Food Chem.</source><year>2020</year><volume>68</volume><fpage>6464</fpage><lpage>6484</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.0c01554</pub-id><pub-id pub-id-type="pmid">32441927</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karabegovi&#263;</surname><given-names>I</given-names></name><name name-style="western"><surname>Portilla-Fernandez</surname><given-names>E</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Maas</surname><given-names>SCE</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D</given-names></name><name name-style="western"><surname>Hu</surname><given-names>EA</given-names></name><name name-style="western"><surname>K&#252;hnel</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ambatipudi</surname><given-names>S</given-names></name><name name-style="western"><surname>Fiorito</surname><given-names>G</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Castillo-Fernandez</surname><given-names>JE</given-names></name><name name-style="western"><surname>Wiggins</surname><given-names>KL</given-names></name><name name-style="western"><surname>de Klein</surname><given-names>N</given-names></name><name name-style="western"><surname>Grioni</surname><given-names>S</given-names></name><name name-style="western"><surname>Swenson</surname><given-names>BR</given-names></name><name name-style="western"><surname>Polidoro</surname><given-names>S</given-names></name><name name-style="western"><surname>Treur</surname><given-names>JL</given-names></name><name name-style="western"><surname>Cuenin</surname><given-names>C</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>PC</given-names></name><name name-style="western"><surname>Costeira</surname><given-names>R</given-names></name><name name-style="western"><surname>Chajes</surname><given-names>V</given-names></name><name name-style="western"><surname>Braun</surname><given-names>K</given-names></name><name name-style="western"><surname>Verweij</surname><given-names>N</given-names></name><name name-style="western"><surname>Kretschmer</surname><given-names>A</given-names></name><name name-style="western"><surname>Franke</surname><given-names>L</given-names></name><name name-style="western"><surname>van Meurs</surname><given-names>JBJ</given-names></name><name name-style="western"><surname>Uitterlinden</surname><given-names>AG</given-names></name><name name-style="western"><surname>de Knegt</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>MA</given-names></name><name name-style="western"><surname>Dehghan</surname><given-names>A</given-names></name><name name-style="western"><surname>Peters</surname><given-names>A</given-names></name><name name-style="western"><surname>Sch&#246;ttker</surname><given-names>B</given-names></name><name name-style="western"><surname>Gharib</surname><given-names>SA</given-names></name><name name-style="western"><surname>Sotoodehnia</surname><given-names>N</given-names></name><name name-style="western"><surname>Bell</surname><given-names>JT</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>P</given-names></name><name name-style="western"><surname>Vineis</surname><given-names>P</given-names></name><name name-style="western"><surname>Relton</surname><given-names>C</given-names></name><name name-style="western"><surname>Herceg</surname><given-names>Z</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>H</given-names></name><name name-style="western"><surname>Waldenberger</surname><given-names>M</given-names></name><name name-style="western"><surname>Rebholz</surname><given-names>CM</given-names></name><name name-style="western"><surname>Voortman</surname><given-names>T</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Fornage</surname><given-names>M</given-names></name><name name-style="western"><surname>Levy</surname><given-names>D</given-names></name><name name-style="western"><surname>Kayser</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghanbari</surname><given-names>M</given-names></name></person-group><article-title>Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>2830</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22752-6</pub-id><pub-id pub-id-type="pmid">33990564</pub-id><pub-id pub-id-type="pmcid">PMC8121846</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>